• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Late-breaking data supports Abbott FreeStyle Libre 3 in 14-day glucose monitoring

June 6, 2022 By Sean Whooley

Abbott FreeStyle Libre 3 sensor pennies CGM diabetes
The sensor for the next-generation FreeStyle Libre 3 CGM is the same size as two U.S. pennies stacked together. [Image courtesy of Abbott]
Abbott (NYSE:ABT) announced data demonstrating the accuracy of its next-generation FreeStyle Libre 3 continuous glucose monitor (CGM).

The latest version of the company’s FreeStyle Libre platform — designed as the smallest and thinnest CGM sensor in the world at the size of just two stacked U.S. pennies — picked up FDA clearance for people with diabetes aged four years old and up just last week.

Late-breaking data highlighting the mean absolute relative difference (MARD) — a measure of sensor accuracy — for the recently cleared CGM was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Abbott said in a news release that the data, which demonstrated an overall MARD of 7.9%, makes FreeStyle Libre 3 the first and only 14-day CGM to achieve a sub-8% overall MARD

The multi-center study evaluated FreeStyle Libre 3 in people with type 1 or type 2 diabetes aged four years and older who were on insulin therapy. MARD values totaled 7.6% for adults age 18 and up and 8.7% for children between 6-17. For children between 4-5, MARD was 10.1%.

“Abbott revolutionized glucose monitoring with our world-leading FreeStyle Libre technology — the first sensor to eliminate painful fingersticks by offering factory-calibrated continuous glucose monitoring that is affordable, accessible and accurate,” Abbott divisional VP of Global Medical Affairs and CMO of Diabetes Care Dr. Mahmood Kazemi said in the release. “A sub-8% overall MARD for the FreeStyle Libre 3 system is a significant milestone, not just in terms of CGM innovation, but because it empowers people with diabetes to be more confident when making important diabetes management decisions.”

Further data presented by Abbott at ADA showed that FreeStyle Libre helps prevent therapeutic inertia and that the company’s new glucose pattern insights report in the LibreView software platform helps primary care providers identify and treat hypoglycemia events that are missed when using standardized reports.

An analysis of retrospective data collected over 24 months from more than 370,000 patients with type 2 diabetes in Canada showed that FreeStyle Libre data helped clinicians make earlier decisions or adjustments to type 2 diabetes treatments versus making decisions based on conventional blood glucose monitoring, the company said.

Its comparative study showed that LibreView’s glucose pattern insights better identify patterns of poor glycemic control and offer considerations for the clinician, Abbott said.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, American Diabetes Association

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS